Literature DB >> 15526160

Signal transduction via the stem cell factor receptor/c-Kit.

L Rönnstrand1.   

Abstract

Together with its ligand, stem cell factor, the receptor tyrosine kinase c-Kit is a key controlling receptor for a number of cell types, including hematopoietic stem cells, mast cells, melanocytes and germ cells. Gain-of-function mutations in c-Kit have been described in a number of human cancers, including testicular germinomas, acute myeloid leukemia and gastrointestinal stromal tumors. Stimulation of c-Kit by its ligand leads to dimerization of receptors, activation of its intrinsic tyrosine kinase activity and phosphorylation of key tyrosine residues within the receptor. These phosphorylated tyrosine residues serve as docking sites for a number of signal transduction molecules containing Src homology 2 domains, which will thereby be recruited to the receptor and activated many times through phosphorylation by the receptor. This review discusses our current knowledge of signal transduction molecules and signal transduction pathways activated by c-Kit and how their activation can be connected to the physiological outcome of c-Kit signaling.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15526160     DOI: 10.1007/s00018-004-4189-6

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  129 in total

Review 1.  Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics.

Authors:  Scott E Woodman; Michael A Davies
Journal:  Biochem Pharmacol       Date:  2010-05-08       Impact factor: 5.858

2.  c-kit (CD117) expression in human tumors and its prognostic value: an immunohistochemical analysis.

Authors:  Michael Medinger; Manuela Kleinschmidt; Klaus Mross; Barbara Wehmeyer; Clemens Unger; Hans-Eckart Schaefer; Renate Weber; Marc Azemar
Journal:  Pathol Oncol Res       Date:  2010-02-23       Impact factor: 3.201

3.  Structural basis for c-KIT inhibition by the suppressor of cytokine signaling 6 (SOCS6) ubiquitin ligase.

Authors:  Fahad Zadjali; Ashley C W Pike; Mattias Vesterlund; Jianmin Sun; Chenggang Wu; Shawn S C Li; Lars Rönnstrand; Stefan Knapp; Alex N Bullock; Amilcar Flores-Morales
Journal:  J Biol Chem       Date:  2010-10-28       Impact factor: 5.157

4.  Heterozygous kit mutants with little or no apparent anemia exhibit large defects in overall hematopoietic stem cell function.

Authors:  Yashoda Sharma; Clinton M Astle; David E Harrison
Journal:  Exp Hematol       Date:  2007-02       Impact factor: 3.084

5.  The emerging role of matrix metalloproteases of the ADAM family in male germ cell apoptosis.

Authors:  Ricardo D Moreno; Paulina Urriola-Muñoz; Raúl Lagos-Cabré
Journal:  Spermatogenesis       Date:  2011-07-01

Review 6.  Growth factors and oncogenes as targets in melanoma: lost in translation?

Authors:  Lawrence Kwong; Lynda Chin; Stephan N Wagner
Journal:  Adv Dermatol       Date:  2007

7.  The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction.

Authors:  Jianmin Sun; Malin Pedersen; Lars Rönnstrand
Journal:  J Biol Chem       Date:  2009-03-05       Impact factor: 5.157

8.  KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.

Authors:  Amie S Corbin; Thomas O'Hare; Zhimin Gu; Ira L Kraft; Anna M Eiring; Jamshid S Khorashad; Anthony D Pomicter; Tian Y Zhang; Christopher A Eide; Paul W Manley; Jorge E Cortes; Brian J Druker; Michael W Deininger
Journal:  Cancer Res       Date:  2013-07-25       Impact factor: 12.701

9.  Spatial and temporal expression of c-Kit in the development of the murine submandibular gland.

Authors:  Xuejiu Wang; Senrong Qi; Jinsong Wang; Dengsheng Xia; Lizheng Qin; Zongmei Zheng; Liping Wang; Chunmei Zhang; Luyuan Jin; Gang Ding; Songlin Wang; Zhipeng Fan
Journal:  J Mol Histol       Date:  2014-02-20       Impact factor: 2.611

Review 10.  The tyrosine kinase network regulating mast cell activation.

Authors:  Alasdair M Gilfillan; Juan Rivera
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.